Evidence map›Paper›PMID 41797924›Full record

ArticleiScience2026

WNT7B drives a program for pancreatic cancer subtype switching and progression.

Joep Sprangers, Jeroen M Bugter, Despina Xanthakis, Michiel Boekhout, Rutger N U Kok, Veerle E Geurts, Hans Clevers, Lodewijk A A Brosens, Frederike Dijk, Maria J Rodríguez Colman and 2 more

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Joep SprangersOncode Institute, Utrecht, the Netherlands.
Jeroen M BugterOncode Institute, Utrecht, the Netherlands.
Despina XanthakisOncode Institute, Utrecht, the Netherlands.
Michiel BoekhoutOncode Institute, Utrecht, the Netherlands.
Rutger N U KokOncode Institute, Utrecht, the Netherlands.
Veerle E GeurtsOncode Institute, Utrecht, the Netherlands.
Hans CleversOncode Institute, Utrecht, the Netherlands.
Lodewijk A A BrosensDepartment of Pathology, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, the Netherlands.
Frederike DijkDepartment of Gynaecologic Oncology, Amsterdam University Medical Centres, Amsterdam, the Netherlands.
Maria J Rodríguez ColmanOncode Institute, Utrecht, the Netherlands.
Jelte Y van der VaartOncode Institute, Utrecht, the Netherlands.
Madelon M MauriceOncode Institute, Utrecht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperactivation of WNT signaling is a hallmark of cancer, often driven by increased expression of WNT ligands. In pancreatic ductal adenocarcinoma (PDAC), elevated WNT7B and WNT10A correlate with aggressive, basal-like disease and poor patient survival, but the mechanisms underlying this association remain unclear. Using patient-derived organoids, we show that WNT7B promotes proliferation and maintains basal-like transcriptional states by preventing differentiation toward a more classical PDAC signature. Clonal WNT7B reporter organoids reveal that WNT-high cells are heterogeneously distributed and stably coexist with WNT-low/negative lineages. Hybrid co-cultures demonstrate that WNT7B-expressing cells support the survival and growth of neighboring WNT-negative cells via short-range, contact-dependent signaling. These findings highlight the functional importance of heterogeneous WNT7B/10A expression in driving PDAC aggressiveness and suggest that targeted WNT inhibition may shift tumors toward a more differentiated, less aggressive state, offering potential therapeutic benefit.

Indexed as

cancercell biologyfunctional aspects of cell biology

Identifiers

PMID41797924
PMCPMC12961301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.